Metabolic
The GLP-1 research landscape in 2026
8 min read · 21/08/2026
Where incretin research has moved since the first dual agonists, and what comparators labs are using now.
Incretin research has expanded rapidly from single GLP-1 agonism to dual and triple receptor targets.
## Single agonists Semaglutide remains the most widely used reference compound in glucose-handling models.
## Dual agonists Tirzepatide introduced GIP receptor activity alongside GLP-1, and is now a standard comparator.
## What to watch Triple agonists targeting glucagon receptors are the current frontier in published preclinical work.
References
- Incretin-based therapies: preclinical review, Diabetologia
This article is educational and summarises published research. It is not medical advice. All Welcuren treatments require an online consultation and are only ever prescribed at a clinician's discretion.